IP Library › Granted Patent US 12,458,705
Granted Patent B2
US 12,458,705 · App. 17/251,316 · Granted Nov 4, 2025

Antibody-oligonucleotide conjugates

Inventors: Paul A. Jaminet (Cambridge, MA); Shou-Ching S. Jaminet (Cambridge, MA); Edward Ha (Cambridge, MA)
Assignee: ANGIEX, INC.
A61K47/6807A61K45/06A61K47/6849A61K47/6855A61P35/00C07K16/28C07K19/00C12N15/113C12N15/1135C12N15/1137C12N15/1138C07K2317/55C12N2310/11C12N2310/14C12N2310/141C12N2310/3513C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,458,705
App. No.
17/251,316
Granted
Nov 4, 2025
Kind
B2
Abstract

Conjugates are provided, comprising a targeting protein, e.g., an anti-TM4SFI antibody or antigen or binding fragments thereof. Methods of manufacture and use of said conjugates are also described.

Claims (21)

1 . A conjugate comprising an anti-TM4SF 1 antibody or an antigen binding fragment thereof conjugated to an oligonucleotide,

(1) wherein the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 94, 95, and 96, respectively, and a light chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 97, 98, and 99, respectively, and wherein optionally the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain sequence of SEQ ID NO.: 92 and a light chain sequence of SEQ ID NO.: 93;

(2) wherein the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain sequence of SEQ ID NO.: 1 and a light chain sequence of SEQ ID NO.: 2;

(3) wherein the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 6, 7, and 8, respectively, and a light chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 12, 13, and 14, respectively, and wherein optionally the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain sequence of SEQ ID NO.: 3 and a light chain sequence of SEQ ID NO.: 9;

(4) wherein the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 18, 19, and 20, respectively, and a light chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 24, 25, and 26, respectively, and wherein optionally the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain sequence of SEQ ID NO.: 15 and a light chain sequence of SEQ ID NO.: 21;

(5) wherein the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 30, 31, and 32, respectively, and a light chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 36, 37, and 38, respectively, and wherein optionally the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain sequence of SEQ ID NO.: 27 and a light chain sequence of SEQ ID NO.: 33;

(6) wherein the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 54, 55, and 56, respectively, and a light chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 60, 61, and 62, respectively, and wherein optionally the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain sequence of SEQ ID NO.: 51 and a light chain sequence of SEQ ID NO.: 57;

(7) wherein the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 66, 67, and 68, respectively, and a light chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 72, 73, and 74, respectively, and wherein optionally the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain sequence of SEQ ID NO.: 63 and a light chain sequence of SEQ ID NO.: 69;

(8) wherein the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 78, 79, and 80, respectively, and a light chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 84, 85, and 86, respectively, and wherein optionally the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain sequence of SEQ ID NO.: 75 and a light chain sequence of SEQ ID NO.: 81; or

(9) wherein the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 42, 43, and 44, respectively, and a light chain CDR1, CDR2, and CDR3 sequence of SEQ ID NO.: 48, 49, and 50, respectively, the anti-TM4SF1 antibody or an antigen binding fragment thereof comprises a heavy chain sequence of SEQ ID NO.: 39 and a light chain sequence of SEQ ID NO.: 45.

2 . The conjugate of claim 1 , wherein the oligonucleotide comprises a DNA molecule or an RNA molecule.

3 . The conjugate of claim 2 , wherein the oligonucleotide comprises the RNA molecule, and wherein the oligonucleotide comprises an antisense oligonucleotide, an siRNA, an antisense RNA, an miRNA, an antisense miRNA, an antagomir (anti-miRNA), an shiRNA, or an mRNA.

4 . The conjugate of claim 2 , wherein the oligonucleotide comprises the DNA molecule, and wherein the oligonucleotide comprises a modified DNA, a triple helical DNA, a supercoiled DNA, a Z-DNA, or any combinations thereof.

5 . The conjugate of claim 3 , wherein the oligonucleotide comprises the siRNA comprising a trinucleotide repeat.

6 . The conjugate of claim 5 , wherein the siRNA is a CAG/CUG trinucleotide repeat based siRNA.

7 . A composition comprising a conjugate according to claim 1 in combination with an antibody-drug conjugate.

8 . The composition of claim 7 , wherein the antibody-drug conjugate comprises a cytotoxic payload.

9 . The composition of claim 8 , wherein the cytotoxic payload comprises a V-ATPase inhibitor, a pro-apoptotic agent, a Bcl2 inhibitor, an MCL1 inhibitor, a HSP90 inhibitor, an 1AP inhibitor, an mTor inhibitor, a microtubule stabilizer, a microtubule destabilizer, an auri statin, a dolastatin, a maytansinoid, a MetAP (methionine aminopeptidase), an inhibitor of nuclear export of proteins CRM1, a DPPIV inhibitor, proteasome inhibitors, inhibitors of phosphoryl transfer reactions in mitochondria, a protein synthesis inhibitor, a kinase inhibitor, a CDK2 inhibitor, a CDK9 inhibitor, a kinesin inhibitor, an HD AC inhibitor, a DNA damaging agent, a DNA alkylating agent, a DNA intercalator a DNA minor groove binder, a DHFR inhibitor, a nucleic acid, or a CRISPR enzyme.

10 . The composition of claim 7 , wherein the antibody-drug conjugate comprises an anti-TM4SF 1 antibody or an antigen binding fragment thereof.

11 . The conjugate of claim 3 , wherein the oligonucleotide hybridizes with a polynucleotide encoding an inhibitor of p53.

12 . The conjugate of claim 3 , wherein the oligonucleotide hybridizes with a polynucleotide encoding an apoptosis inhibitor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2021
From: JAMINET, PAUL A.; JAMINET, SHOU-CHING S.; HA, EDWARD
To: ANGIEX, INC.
Reel/Frame 055269/0499 →
Continuity (2)
Provisional Application 62684131 · Jun 12, 2018
Related Publication 20210260209A1 · Aug 26, 2021
References Cited (165)
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 3854480A · Zaffaroni · 1974 [cited by applicant]
US 3887699A · Yolles · 1975 [cited by applicant]
US 4452775A · Kent · 1984 [cited by applicant]
US 4485045A · Regen · 1984 [cited by applicant]
US 4544545A · Ryan et al. · 1985 [cited by applicant]
US 4675189A · Kent et al. · 1987 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5133974A · Paradissis et al. · 1992 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5407686A · Patel et al. · 1995 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5654010A · Johnson et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5736152A · Dunn · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6372716B1 · Bush et al. · 2002 [cited by applicant]
US 6566329B1 · Meyn et al. · 2003 [cited by applicant]
US 6685940B2 · Andya et al. · 2004 [cited by applicant]
US 6982321B2 · Winter · 2006 [cited by applicant]
US 7087409B2 · Barbas, III et al. · 2006 [cited by applicant]
US 7527791B2 · Adams et al. · 2009 [cited by applicant]
US 10155812B2 · Jaminet et al. · 2018 [cited by applicant]
US 11208495B2 · Jaminet · 2021 [cited by examiner]
US 20030235584A1 · Kloetzer et al. · 2003 [cited by applicant]
US 20060030003A1 · Simon · 2006 [cited by examiner]
US 20060030015A1 · Uda et al. · 2006 [cited by applicant]
US 20120004117A1 · Aburatani et al. · 2012 [cited by applicant]
US 20160194402A1 · Van Eenennaam et al. · 2016 [cited by applicant]
CA 1176565A · 1984 [cited by applicant]
CN 105934252A · 2016 [cited by applicant]
DE 3218121A1 · 1983 [cited by applicant]
EP 0036676A1 · 1981 [cited by applicant]
EP 0052322A2 · 1982 [cited by applicant]
EP 0058481A1 · 1982 [cited by applicant]
EP 0088046A2 · 1983 [cited by applicant]
EP 0102324A2 · 1984 [cited by applicant]
EP 0142641A2 · 1985 [cited by applicant]
EP 0143949A1 · 1985 [cited by applicant]
EP 0158277A2 · 1985 [cited by applicant]
EP 0239400A2 · 1987 [cited by applicant]
EP 0517565A2 · 1992 [cited by applicant]
EP 0519596A1 · 1992 [cited by applicant]
EP 0592106A1 · 1994 [cited by applicant]
EP 1951890A4 · 2009 [cited by applicant]
EP 3315139A1 · 2018 [cited by examiner]
WO WO9109967A1 · 1991 [cited by applicant]
WO WO9209690A2 · 1992 [cited by applicant]
WO WO9315722A1 · 1993 [cited by applicant]
WO WO9607399A1 · 1996 [cited by applicant]
WO WO9629998A1 · 1996 [cited by applicant]
WO WO9640072A2 · 1996 [cited by applicant]
WO WO9703692A1 · 1997 [cited by applicant]
WO WO9951642A1 · 1999 [cited by applicant]
WO WO2004009664A2 · 2004 [cited by applicant]
WO WO2005087201A1 · 2005 [cited by applicant]
WO WO2005100402A1 · 2005 [cited by applicant]
WO WO2006029879A2 · 2006 [cited by applicant]
WO WO2007070659A2 · 2007 [cited by applicant]
WO WO2007079130A2 · 2007 [cited by applicant]
WO WO2007094916A2 · 2007 [cited by applicant]
WO WO2008077079A1 · 2008 [cited by applicant]
WO WO2008083346A1 · 2008 [cited by applicant]
WO WO2009045536A2 · 2009 [cited by applicant]
WO WO2010037062A1 · 2010 [cited by applicant]
WO WO2011028195A2 · 2011 [cited by applicant]
WO WO2012166559A1 · 2012 [cited by applicant]
WO WO2012166560A1 · 2012 [cited by applicant]
WO WO2015054427A1 · 2015 [cited by applicant]
WO WO2019046338A1 · 2019 [cited by examiner]
WO WO2019241430A2 · 2019 [cited by applicant]
Gong et al. Bioconjugate Chemistry 2016, 27:217-235. (Year: 2016). [cited by examiner]
Janeway Jr et al., Immunology, 3rd Edition, 1997 Garland Publishing Inc., pp. 3:1-3:11. (Year: 1997). [cited by examiner]
Edwards et al. J. Mol. Biol., 2003, 334:103-118. (Year: 2003). [cited by examiner]
Lloyd et al. Protein Engineering Design & Selection 2009, 22;3:159-168. (Year: 2009). [cited by examiner]
Goel et al. The Journal of Immunology, 2004, 173:7358-7367. (Year: 2004). [cited by examiner]
Kanyavuz et al. Nature Review Immunology, 2019, 19: 355-368. (Year: 2019). [cited by examiner]
International Search Report and Written Opinion dated Dec. 2, 2019 for PCT/US2019/036836. [cited by applicant]
Karaki et al., Lipid-oligonucleotide conjugates improve cellular update and efficiency of TCTP-antisense in castration-resistant prostrate cancer, J Control Release, Jul. 2017, 258:1-9. [cited by applicant]
Lin, Chi-Lou et al., TM4SF!: A new vascular therapeutic target in cancer, Angiogenesis, Oct. 2014; 17(4):897-907. [cited by applicant]
Murmann, et al., Small interfering RNAs based on huntington trinucleotide repeats are highly toxic to cancer cells, EMBO Rep. Mar. 2018, 19(3). [cited by applicant]
Sciuto et al., Intracellular distribution of TM4SF1 and internalization of TM4SF1-antibody complex in vascular endothelial cells, Biochem Biophys Res Commun, Aug. 1, 2015, vol. 45, pp. 338-343. [cited by applicant]
Visintin, et al., Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature, Mmol Cancer Ther, Jun. 18, 2015, vol. 14, pp. 1868-1876. [cited by applicant]
Zhu, Haibin et al., RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells, Medical Oncology vol. 28, pp. 381-387 (2011). [cited by applicant]
Almagro et al.: Humanization of Antibodies. Frontiers in Bioscience 13:1619-1633 (2008). [cited by applicant]
Altschul et al., Gapped BLAST and PSI-Blast: A New Generation Of Protein Database Search Programs. Nucleic Acids Research 25(17):3389-3402 (1997). [cited by applicant]
An Z et al.: IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs. 1(6):572-9 (2009). [cited by applicant]
Angal et al.: A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.Mol Immunol. 30(1):105-108 (1993). [cited by applicant]
Baca et al.: Antibody humanization using monovalent phage display. J Biol Chem 272(16):10678-10684 (1997). [cited by applicant]
Bass et al.: Hormone phage: an enrichment method for variant proteins with altered binding properties. Proteins. 8(4):309-314 (1990). [cited by applicant]
Brennan et al.: Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin fragments. Science 229:81-83 (1985). [cited by applicant]
Brodeur et al.: In: Monoclonal Antibody Production Techniques and Applications. New York: Marcel Dekker:51-63 (1987). [cited by applicant]
Bruggemann et al.: Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies. J. Exp. Med. 166:1351-1361 (1987). [cited by applicant]
Carter et al.: Humanization of an anti-p185HER2 antibody for human cancer therapy. PNAS USA 89(10):4285-4289 (1992). [cited by applicant]
Chang et al.: CD13 (Aminopeptidase N) Can Associate With Tumor-Associated Antigen L6 and Enhance the Motility of Human Lung Cancer Cells, IntJ Cancer. 1(16): 243-252 (2005). [cited by applicant]
Chaudhary et al.: A rapid method of cloning functional variable-region antibody genes in [cited by applicant]
Chen et al.: Selection And Analysis Of An Optimized Anti-VEGF Antibody: Crystal Structure Of An Affinity-matured Fab In Complex With Antigen. Journal of Molecular Biology 293(4):865-881 (1999). [cited by applicant]
Chinese Patent Application No. 201980054038.8 Office Action dated Aug. 26, 2023. [cited by applicant]
Chothia et al.: Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196:901-917 (1987). [cited by applicant]
Chothia et al., Conformations Of Immunoglobulin Hypervariable Regions. Nature 342(6252):877-883 (1989). [cited by applicant]
Clynes et al.: Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A. 95(2):652-6 (1998). [cited by applicant]
Cragg et al.: Antibody specificity controls in vivo effector mechanisms of aniti-CD20 reagents, Blood 103:2738-2743 (2004). [cited by applicant]
Cragg et al.: Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101(3):1045-1052 (2003). [cited by applicant]
Cuellar et al. Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res 43(2):1189-1203 (2015). [cited by applicant]
Dall'Acqua, et al.: Antibody humanization by framework shuffling. Methods. 36(1):43-60 (2005). [cited by applicant]
Gazzano-Santoro et al.: A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods 202(2):163-171 (1997). [cited by applicant]
Griffiths et al.: Human anti-self antibodies with high specificity from phage display libraries. Embo J. 12(2):725-734 (1993). [cited by applicant]
Hellstrom et al.: Antitumor Effects of L6, and IgG2a Antibody that Reacts with Most Human Carcinomas. Proceedings of the National Academy of Sciences. National Academy of Sciences. US 83(18):7059-7063 (1986). [cited by applicant]
Hellstrom et al.: Monoclonal Mouse Antibodies Raised Against Human Lung Carcinoma Cancer Research, 46(8):3917-3923 (1986). [cited by applicant]
Hezareh et al. Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody Against Human Immunodeficiency Virus Type 1. Journal of Virology 75(24):12161-12168 (2001). [cited by applicant]
Honegger, A et al., Yet Another Numbering Scheme For Immunoglobulin Variable Domains: An Automatic Modeling And Analysis Tool. Journal of Molecular Biology 309(3):657-670 (2001). [cited by applicant]
Hudes et al.: Temsirolimus, Interferon Alfa, or Both for Advanced Renal-cell Carcinoma. The New England Journal of Medicine 356(22):2271-2281 (2007). [cited by applicant]
Hudson et al.: Engineered Antibodies. Nature Medicine 9(1):129-134 (2003). [cited by applicant]
Idusogie et al.: Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 164(8):4178-84 (2000). [cited by applicant]
Japanese Patent Application No. 2020-569176 Office Action dated Oct. 10, 2023. [cited by applicant]
Jones et al., Replacing The Complementarity-determining Regions In A Human Antibody With Those From A Mouse. Nature 321(6069):522-525 (1986). [cited by applicant]
Karlin, S, et al., Applications And Statistics For Multiple High-scoring Segments In Molecular Sequences. Proceedings of the National Academy of Sciences of the United States of America 90(12):5873-5877 (1993). [cited by applicant]
Kashmiri et al.: SDR grafting—a new approach to antibody humanization, Methods vol. 36, No. 1, pp. 25-34 (2005). [cited by applicant]
Khidekel et al.: A Chemoenzymatic Approach Toward the Rapid and Sensitive Detection of O-GlcNAc Posttranslational Modifications. Journal of the American Chemical Society 125(52):16162-16163 (2003). [cited by applicant]
Klimka et al.: Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning. British Journal of Cancer. 83(2):252-260 (2000). [cited by applicant]
Kohler et al.: Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity. Nature 256(5517):495-497 (1975). [cited by applicant]
Kozbor.: A human hybrid myeloma for production of human monoclonal antibodies. Immunol. 133:3001-05 (1984). [cited by applicant]
Levengood et al.: Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates. Angew Chem Int Ed England 56(3):733-737 (2017). [cited by applicant]
Liu et al.: Synthesis of 2'-paclitaxel Methyl 2-glucopyranosyl succinate for Specific Targeted Delivery to Cancer Cells. Bioorganic & medicinal chemistry letters 17(3):617-620 (2007). [cited by applicant]
Maccallum, R M, et al., Antibody-Antigen Interactions: Contact Analysis And Binding Site Topography. Journal of Molecular Biology 262(5):732-745 (1996). [cited by applicant]
Morimoto et al.: Single-step purification of F(ab')2 Fragments of Mouse Monoclonal Antibodies (Immunoglobulins G1) by Hydrophobic Interaction High Performance Liquid Chromatography using TSKgel Phenyl-5PW. J Biochem Bio… [cited by applicant]
Morris: Epitope Mapping Protocols. Methods in Molecular Biology. 66:1-9 (1996). [cited by applicant]
Morrison et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. PNAS USA 81(21):6851-6855 (1984). [cited by applicant]
Munson et al.: Ligand a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107(1):220-239 (1980). [cited by applicant]
Osbourn et al.: From rodent reagents to human therapeutics using antibody guided selection. Methods 36(1):61-68 (2005). [cited by applicant]
Padlan, et al.: A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol 28(4-5):489-498 (1991). [cited by applicant]
Padlan et al.: Identification of specificity-determining residues in antibodies. Faseb J 9(1):133-9 (1995). [cited by applicant]
Pearson W.R.: Using the FASTA Program to Search Protein and DNA Sequence Databases. Meth. Mol. Biol 24:307-331 (1994). [cited by applicant]
Petkova et al.: Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18(12):1759-1769 (2006). [cited by applicant]
Pluckthun A.: Mono-and bivalent antibody fragments produced in [cited by applicant]
Presta et al.: Humanization of an antibody directed against IgE. J Immunol 151:2623-2632 (1993). [cited by applicant]
Queen et al., A humanized antibody that binds to the interleukin 2 receptor. PNAS USA 86:10029-10033 (1989). [cited by applicant]
Rabuka David et al.: Site-Specific chemical protein conjugation using genetically encoded aldehyde tags. Nat. Protoc 7(6):1052-1067 (2012). [cited by applicant]
Richman et al.: Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 55(23 Suppl):5916s-5920s (Dec.… [cited by applicant]
Riechmann et al., Reshaping human antibodies for therapy. Nature 332(6162):323-327 (1988). [cited by applicant]
Roberts et al.: Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54: 459-476 (2002). [cited by applicant]
Roguska et al.: Humanization of murine monoclonal antibodies through variable domain resurfacing. PNAS USA 91:969-973 (1994). [cited by applicant]
Rosok et al.: A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab. J Biol Chem 271:22611-22618 (1996). [cited by applicant]
Rychly, et al., Therapeutic Strategies in Autoimmune Diseases by Interfering With Leukocyte Endothelium Interaction Curr Pharm Des. 12(29):3799-806 (2006). [cited by applicant]
Saxena and Christofori, Rebuilding cancer metastasis in the mouse, Mol Oncol 7(2):283-96 (2013). [cited by applicant]
Shih et al.: The L6 Protein TM4SF1 is Critical for Endothelial Cell Function and Tumor Angiogenesis, Available in PMC Apr. 15, 2010, published in final edited form as: Cancer Res. 69(8):3272-3277 (2009). [cited by applicant]
Silva et al.: The S228P Mutation Prevents in Vivo and in Vitro IgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation. JBiol Chem. 290(9):5462-9… [cited by applicant]
Sims et al.: A humanized CD18 antibody can block function without cell destruction., J. Immunol. 151:2296-308 (1993). [cited by applicant]
Skerra A.: Bacterial expression of immunoglobulin fragments. Curr Opin Immunol 5(2):256-262(1993). [cited by applicant]
Studnicka et al.: Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng. 7(6):805-814 (1994). [cited by applicant]
Sugo et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control release 237:1-13 (2016). [cited by applicant]
Uckun et al.: Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia. Integrative Biology. 5:122-132 (2013) DOI:10.1039/c2ib20114c. [cited by applicant]
Verhoeyen et al.: Reshaping human antibodies: Grafting an antilysozyme activity. Science 239:1534-1536 (1988). [cited by applicant]
Wang et al.: Expanding the genetic code. Angew Chem Int Ed, 44(1):34-66(2004). [cited by applicant]
Winter et al.: Making Antibodies by Phage Display Technology. Ann. Rev. Immunol 12:433-55 (1994). [cited by applicant]
Wright et al.: The L6 membrane proteins—A new four-transmembrane superfamily, Protein Sci. 9: 1594-1600 (2000). [cited by applicant]
Yang NJ et al.: Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins. Nucleic Acids Res 45(13):7602-7614 (2017). [cited by applicant]
Zukauskas et al.: TM4SF1: A tetraspanin-like protein necessary for nanopodia formation and endothelial cell migration, Available in PMC Mar. 11, 2012, published in final edited form as: Angiogenesis. 14(3):345-354 (2011… [cited by applicant]
Dowdy et al.: Delivery of RNA Therapeutics: The Great Endosomal Escape! Nucleic Acid Therapeutics. 32(5):361-368 (2022). [cited by applicant]